Header

UZH-Logo

Maintenance Infos

The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure


Nijenhuis, V J; Sanchis, L; van der Heyden, J A S; Klein, P; Rensing, B J W M; Latib, A; Maisano, F; Ten Berg, J M; Agostoni, P; Swaans, M J (2017). The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure. Netherlands Heart Journal, 25(10):536-544.

Abstract

Heart failure has a high prevalence in the general population. Morbidity and mortality of heart failure patients remain high, despite improvements in drug therapy, implantable cardioverter-defibrillators and cardiac resynchronisation therapy. New transcatheter implantable devices have been developed to improve the treatment of heart failure. There has been a rapid development of minimally invasive or transcatheter devices used in the treatment of heart failure associated with aortic and mitral valve disease and these devices are being incorporated into routine clinical practice at a fast rate. Several other new transcatheter structural heart interventions for chronic heart failure aimed at a variety of pathophysiologic approaches are currently being developed. In this review, we focus on devices used in the treatment of chronic heart failure by means of left ventricular remodelling, left atrial pressure reduction, tricuspid regurgitation reduction and neuromodulation. The clinical evaluations of these devices are early-stage evaluations of initial feasibility and safety studies and additional clinical evidence needs to be gathered in appropriately designed clinical trials.

Abstract

Heart failure has a high prevalence in the general population. Morbidity and mortality of heart failure patients remain high, despite improvements in drug therapy, implantable cardioverter-defibrillators and cardiac resynchronisation therapy. New transcatheter implantable devices have been developed to improve the treatment of heart failure. There has been a rapid development of minimally invasive or transcatheter devices used in the treatment of heart failure associated with aortic and mitral valve disease and these devices are being incorporated into routine clinical practice at a fast rate. Several other new transcatheter structural heart interventions for chronic heart failure aimed at a variety of pathophysiologic approaches are currently being developed. In this review, we focus on devices used in the treatment of chronic heart failure by means of left ventricular remodelling, left atrial pressure reduction, tricuspid regurgitation reduction and neuromodulation. The clinical evaluations of these devices are early-stage evaluations of initial feasibility and safety studies and additional clinical evidence needs to be gathered in appropriately designed clinical trials.

Statistics

Citations

Altmetrics

Downloads

45 downloads since deposited on 13 Feb 2019
43 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, not_refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Vascular Surgery
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Heart failure Minimally invasiveNeuromodulation Transcatheter Tricuspid regurgitation Ventricular aneurysm
Language:English
Date:October 2017
Deposited On:13 Feb 2019 16:18
Last Modified:25 Sep 2019 00:24
Publisher:Bohn Stafleu van Loghum B.V.
ISSN:1568-5888
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1007/s12471-017-1018-8
PubMed ID:28741245

Download

Green Open Access

Download PDF  'The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure'.
Preview
Content: Published Version
Filetype: PDF
Size: 2MB
View at publisher